Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis

• Published in: Diabetes & metabolism Vol. 51; no. 2; p. 101613
• Main Authors: Nassar, Mahmoud, Abosheaishaa, Hazem, Misra, Anoop, Dandona, Paresh, Ghanim, Husam, Chaudhuri, Ajay
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.03.2025
• Subjects: Acute Disease; Adult; Aged; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; DPP-4i; Female; GLP-1RAs; Glucagon-Like Peptide-1 Receptor Agonists; Humans; Hypoglycemic Agents - therapeutic use; Male; Middle Aged; Pancreatitis; Pancreatitis - chemically induced; Pancreatitis - epidemiology; Recurrence; Retrospective Studies; SGLT2i; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; T2D; TriNetx; DPP-4i; SGLT2i; TriNetx; GLP-1RAs; Pancreatitis; T2D

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used in subjects with type 2 diabetes (T2D) and obesity. However, concerns over their association with acute pancreatitis (AP) have emerged. Our aim was to evaluate the risk of recurrence of AP in subjects on GLP-1RAs with a history of AP. Thi...